Findings from the current study demonstrate that over half of chronic HF patients in the DIG trial had severe and more advanced disease as evidenced by the presence of NYHA III–IV symptoms, LVEF <25%, ...

The benefit of digoxin was driven by reduced risk of new-onset or worsening HF hospitalizations, just like its benefit in ...

MADRID, Spain—Adding digitoxin, a cardiac glycoside, to contemporary guideline-directed medical therapy (GDMT) improves clinical outcomes in patients who have heart failure with reduced ejection ...

Wearable device data could predict New York Heart Association functional class similarly to clinical measures and six-minute walk test. HealthDay News — For patients with atrial fibrillation, digoxin ...

Patients with rheumatic heart disease who took the heart failure drug digoxin were 18% less likely to die or experience new-onset or worsening heart failure during a two-year follow-up compared with ...

Foxglove, a flowering plant long feared for its toxicity, became an unlikely source of a widely studied heart drug. Digoxin, a cardiac glycoside associated in modern medicine with Digitalis species ...

Medical topics worthy of writing about transcend the details of the drug or device and implicate a broader lesson. The medical establishment's turn against digoxin perfectly illustrates this duality.

Prognosis in Patients With Sentinel Node–Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria Two thousand one hundred forty-four of 104,648 women ...